Incretin Atlas › Trials › HDM1702 vs Wegovy (bioequivalence)
HDM1702 vs Wegovy (bioequivalence)
HDM1702 · obesity
Design
- Molecule(s)
- HDM1702
- Population
- obesity
- Phase
- 3
- Participants
- 462
- Duration
- 44 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDM1702 2.4 mg vs semaglutide (Wegovy): −16.27 % | obesity china | 44 | 462 | — | −15.2 % | — | — | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: HDM1702 vs Wegovy (bioequivalence). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1702-vs-wegovy/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.